Core Scientific, Inc./tx
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
7 — Warrant Liabilities
- WARRANT LIABILITIES
On January 23, 2024, the Company entered into a warrant agreement (the “Warrant Agreement”) providing for the issuance of
98,313,313 warrants, each exercisable forone share of common stock at an exercise price of$6.81 per share (the “Tranche 1
Warrants”), and 81,927,898 warrants, each exercisable forone share of common stock at an exercise price of$0.01 per share (the
“Tranche 2 Warrants” and, together with the Tranche 1 Warrants, the “Warrants”). The Tranche 1 Warrants expire on January 23,
2027, and the Tranche 2 Warrants expire on January 23, 2029.
During the three months ended March 31, 2026, nominal Tranche 1 Warrants were exercised, which resulted in cash receipts of
$0.1 million. As of March 31, 2026, there were 96.7 million unexercised Tranche 1 Warrants.
During the three months ended March 31, 2026,0.4 million Tranche 2 Warrants were exercised, which resulted inimmaterial
cash receipts. As of March 31, 2026, there were 7.8 million unexercised Tranche 2 Warrants.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.